CODX stock icon

Co-Diagnostics
CODX

$1.06
4.62%
 

About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Employees: 155

0
Funds holding %
of 6,656 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

146% more call options, than puts

Call options by funds: $98.2K | Put options by funds: $39.9K

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

29% more capital invested

Capital invested by funds: $4.83M [Q3] → $6.25M (+$1.42M) [Q4]

4% more funds holding

Funds holding: 45 [Q3] → 47 (+2) [Q4]

0.76% more ownership

Funds ownership: 14.57% [Q3] → 15.33% (+0.76%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$2
89%
upside
Avg. target
$2.5
136%
upside
High target
$3
183%
upside

3 analyst ratings

positive
0%
neutral
100%
negative
0%
HC Wainwright & Co.
Yi Chen
89%upside
$2
Neutral
Maintained
13 May 2024
HC Wainwright & Co.
Yi Chen
136%upside
$2.5
Neutral
Maintained
15 Mar 2024
HC Wainwright & Co.
Yi Chen
183%upside
$3
Neutral
Reiterated
29 Dec 2023

Financial journalist opinion